ARDS, Human Clinical Trial
Official title:
Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome (A.R.D.S) in Comparison to Interleukin 6 [IL-6]
Verified date | March 2020 |
Source | Ain Shams University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In this prospective study of 60patients, we tested the hypothesis That markedly elevated
levels of plasma von Willebrand factor (VWF) a marker of endothelial cell injury might
predict the development of acute respiratory distress syndrome (A.R.D.S) in risky patients.
We compared our result to IL.6 as control biomarker for A.R.D.S development.
Acute lung injury was quantified on two -point scoring system (Berlin definition of ARDS and
Murray score of acute lung injury).
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once
the patient considered to be risky for A.R.D.S development to obtain their baseline levels),
T=48 (after 48 hours), and T=72 (after 72 hours).
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | September 20, 2021 |
Est. primary completion date | March 20, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients between 18 and 80 years old of both sexes. - risk factor for development of acute respiratory distress syndrome or acute lung injury either by: - Direct lung injury includes: Severe pneumonia (infection), Breathing a vomited stomach contents (aspiration), Breathing harmful fumes or smoke, severe trauma to the chest or other accident that bruises the lungs. - Indirect lung injury includes: sepsis, Severe injury or trauma with shock, blood transfusions , drug overdose acute pancreatitis, fracture of the long bones, near drowning ,anaphylaxis, uremia, fat embolus , and intracranial insult. Exclusion Criteria: - (1) pregnancy; - (2) a preexisting medical condition with a life expectancy less than 3 months - (3) evidence of cardiogenic pulmonary edema - (4) age under 18 years old or above 80 years old - (5) late stages of liver cell failure, renal failure - (6) severe myocardial infarction - (7) deep coma. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | level of vwf at 72 hours | Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours). | 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06444750 -
Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
|
||
Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04274296 -
Advisory Lead ARDS Respirator Management
|
||
Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT03215316 -
Screening Expiratory Flow Limitation by Flow-time Curve
|
N/A | |
Recruiting |
NCT04115514 -
Treatment of ARDS With Instilled T3
|
Phase 2 | |
Not yet recruiting |
NCT05061212 -
The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
|
||
Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
Not yet recruiting |
NCT04556864 -
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
|
||
Recruiting |
NCT04174014 -
Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography
|
N/A | |
Enrolling by invitation |
NCT06164639 -
Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
|
||
Terminated |
NCT05384379 -
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
|
Early Phase 1 | |
Completed |
NCT04375735 -
London's Exogenous Surfactant Study for COVID19
|
Phase 1/Phase 2 | |
Completed |
NCT06224010 -
Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
|
||
Not yet recruiting |
NCT04530188 -
Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS
|
Phase 3 | |
Completed |
NCT03405038 -
Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
|
||
Recruiting |
NCT05148026 -
Regional Citrate Anticoagulation for RRT During V-V ECMO
|
N/A | |
Recruiting |
NCT04390360 -
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
|
N/A | |
Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|